Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | TK1 | P04183 | 3/20 | 0.58 |
| ▸ | TK2 | O00142 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31074294 | 0.86 | LMNA (0.42) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13082855 | 0.84 | LMNA (0.64) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL12060321 | 0.84 | LMNA (0.64) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL22188739 | 0.83 | LMNA (0.40) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL22188734 | 0.82 | TYMS (0.43) | — | |
| SCHEMBL2357026 | 0.81 | TK1 (0.68) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2357020 | 0.81 | TK1 (0.68) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL1527279 | 0.81 | TK1 (0.68) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL6737955 | 0.81 | TK1 (0.64) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13412992 | 0.81 | TK1 (0.64) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642931-A1 | METHODS OF SEQUENCING USING 3´ ALLYL BLOCKED NUCLEOTIDES | Illumina, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250146066-A1 | NUCLEOTIDES WITH A 3' AOM BLOCKING GROUP | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-05-08 | — | — | US | disclosed |
| WO-2024145154-A1 | METHODS OF SEQUENCING USING 3´ ALLYL BLOCKED NUCLEOTIDES | ILLUMINA, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-0210449-B1 | PROLONGED CHEMILUMINESCENCE | MILES INC. (US) | 1993-07-28 | — | — | EP | disclosed |
| US-4950588-A | DETECTION OF NUCLEIC ACID HYBRIDS, ANTIBODIES ANTIGENS | MOLECULAR DIAGNOSTICS, INC. (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0198207-B1 | SPECIFIC IODINATION OF NUCLEIC ACID | MOLECULAR DIAGNOSTICS, INC. (US) | 1989-12-20 | — | — | EP | disclosed |
| EP-0194545-B1 | LABELLING OF OLIGONUCLEOTIDES | MOLECULAR DIAGNOSTICS, INC. (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4853327-A | THE PRECURSOR, AN OXIDIZING AGENT, PEROXIDASE, NITROGENEOUS COMPOUND AND ALKYLAMINE; DETECTION OF NUCLEIC ACID HYBRIDS AND PEROXIDASES; IMMUNOASSAY | MOLECULAR DIAGNOSTICS, INC. (US) | 1989-08-01 | — | — | US | disclosed |
| US-4818681-A | Fast and specific immobilization of nucleic acids to solid supports | MOLECULAR DIAGNOSTICS, INC. (US) | 1989-04-04 | — | — | US | disclosed |
| US-4808520-A | HYBRIDIZING WITH NUCLEIC ACID, THEN WITH NUCLEOSIDE TRIPHOSPHATE IN PRESENCE OF ENZYME | MOLECULAR DIAGNOSTICS, INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4794073-A | Detection of nucleic acid hybrids by prolonged chemiluminescence | MOLECULAR DIAGNOSTICS, INC. (US) | 1988-12-27 | — | — | US | disclosed |
| EP-0210449-A2 | Prolonged chemiluminescence | MILES INC. (US) | 1987-02-04 | — | — | EP | disclosed |
| EP-0198207-A1 | Specific iodination of nucleic acid | MOLECULAR DIAGNOSTICS, INC. (US) | 1986-10-22 | — | — | EP | disclosed |
| EP-0194545-A2 | Labelling of oligonucleotides | MOLECULAR DIAGNOSTICS, INC. (US) | 1986-09-17 | — | — | EP | disclosed |
| EP-0192197-A2 | Fast and specific immobilization of nucleic acids to solid supports | MOLECULAR DIAGNOSTICS, INC. (US) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250146066-A1 | NUCLEOTIDES WITH A 3' AOM BLOCKING GROUP | NT5C3B, NSUN2, RNMT | LMNA 1743/4885SMN1; SMN2 3692/4885ALOX12 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.